Velcade in MALT Lymphoma Patients
NCT00373906 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2013-11-27
Summary
Bortezomib for treatment of disseminated MALT lymphoma or at relapse following HP -eradication,or chemotherapy or radiation.
Conditions
- MALT Lymphoma
Interventions
- DRUG
-
Bortezomib (Velcade)
Sponsors & Collaborators
-
Medical University of Vienna
lead OTHER
Principal Investigators
-
Markus Raderer, Prof · Department of Internal Medicine I
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
NCT00657553 ·Status: TERMINATED ·Phase: PHASE3
-
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
NCT00477412 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
NCT00136565 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00257114 ·Status: COMPLETED ·Phase: PHASE4
-
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
NCT00142129 ·Status: COMPLETED ·Phase: PHASE2
-
Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia
NCT00511069 ·Status: COMPLETED ·Phase: PHASE2
-
Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia
NCT00651781 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
NCT03217812 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
NCT00636792 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
NCT01090921 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function
NCT00718640 ·Status: TERMINATED ·Phase: PHASE2
-
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
NCT01439750 ·Status: UNKNOWN ·Phase: PHASE1
-
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
NCT00334932 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
NCT01162031 ·Status: WITHDRAWN ·Phase: PHASE2
-
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
NCT00287872 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
NCT00715208 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
NCT00377052 ·Status: COMPLETED ·Phase: PHASE2
-
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
NCT00193557 ·Status: COMPLETED ·Phase: PHASE2
-
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
NCT00440765 ·Status: COMPLETED
-
VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)
NCT00311337 ·Status: UNKNOWN ·Phase: PHASE2
-
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
NCT00740415 ·Status: COMPLETED ·Phase: PHASE2
-
Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
NCT00388635 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bortezomib in Treating Patients With Mantle Cell Lymphoma
NCT00030875 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Velcade and Thalidomide in Patients With Myelodysplasia
NCT00271804 ·Status: TERMINATED ·Phase: PHASE1
-
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
NCT00103506 ·Status: COMPLETED ·Phase: PHASE3